Murphy Dennis J
GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA.
Curr Protoc Pharmacol. 2003 Aug;Chapter 10:Unit10.9. doi: 10.1002/0471141755.ph1009s22.
The known effects of drugs from a variety of pharmacological/therapeutic classes on the respiratory system, the life-threatening consequences of respiratory dysfunction, and world-wide regulatory safety guidelines all support the need for conducting respiratory evaluations in safety pharmacology. This unit provides an overview of the functional disorders of the respiratory system and presents the techniques and strategies considered to be most appropriate for detecting and characterizing drug-induced respiratory disorders in safety pharmacology studies.
来自各种药理学/治疗学类别的药物对呼吸系统的已知影响、呼吸功能障碍的危及生命后果以及全球监管安全指南均支持在安全药理学中进行呼吸评估的必要性。本单元概述了呼吸系统的功能障碍,并介绍了在安全药理学研究中被认为最适合检测和表征药物引起的呼吸障碍的技术和策略。